Lantern Pharma Inc. Q4 FY2024 earnings call

• Leadership in innovative use of AI and machine learning to transform drug discovery and development for precision oncology therapies.
• Progress in clinical trials: LP-300 in Phase 2 with accelerated enrollment in Japan and Taiwan; LP-184 and LP-284 in Phase 1 trials with safety profiles established; multiple regulatory designations (Fast Track, rare pediatric) for LP-184.
• Starlight Therapeutics with unique trial design for STAR-001, leveraging AI and data; establishment of Scientific Advisory Board.
• Patent pending blood-brain barrier permeability predictive algorithm and ADC development module using AI, with potential to transform drug development timelines and costs.
• Agentic AI platform development to shift drug development from reactive to proactive, self-learning systems for identifying non-obvious patterns and opportunities.

No specific product segment financial performance with absolute terms and revenue contribution % provided in detail. Focus is on clinical pipelines and AI platform advancements.

• Anticipate mid-to-late Q2 2025 readout for LP-300 Phase 2 trial.
• Enrollment in Asia is 2x to 4x faster than in the U.S. and accelerating.
• Expect more preclinical data on ADC programs and announcements of partnerships using AI platforms later in the year.
• Launch of first agentic AI around blood-brain barrier permeability prediction algorithm and other AI modules in the coming months.

• Factors causing actual results to differ from forward-looking statements, including clinical trial results and competition.
• Uncertainties related to funding and ability to secure additional funding for future operations.

Q: What is missing to sign deals with other firms to discover new drugs?

A: Deals often break down around whether partners are willing to give enough equity in the molecule or upside to make it worth Lantern's while to stop working on its own programs.

Q: Have you reached out to Amazon?

A: Had discussions with Amazon, but need to align on big pharma needs vs. drug developer needs, and working on making Agentic AI architectures publicly available to drive such conversations.